Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MAIA Biotechnology Inc. (MAIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: MAIA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -5.88% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.38M USD | Price to earnings Ratio - | 1Y Target Price 12.13 |
Price to earnings Ratio - | 1Y Target Price 12.13 | ||
Volume (30-day avg) 145783 | Beta 0.39 | 52 Weeks Range 1.41 - 5.99 | Updated Date 04/6/2025 |
52 Weeks Range 1.41 - 5.99 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Earnings Date
Report Date 2025-03-24 | When - | Estimate -0.35 | Actual -0.1972 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -119.61% | Return on Equity (TTM) -1131.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34779673 | Price to Sales(TTM) - |
Enterprise Value 34779673 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 29587300 | Shares Floating 24917844 |
Shares Outstanding 29587300 | Shares Floating 24917844 | ||
Percent Insiders 23.35 | Percent Institutions 4.68 |
Analyst Ratings
Rating 5 | Target Price 12.62 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MAIA Biotechnology Inc.
Company Overview
History and Background
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. It was founded in 2016 and is headquartered in Chicago, Illinois. The company focuses on therapies designed to selectively target and kill cancer cells by activating tumor-specific immune responses.
Core Business Areas
- Drug Development: MAIA Biotechnology develops and commercializes targeted cancer therapies, including those using telomere-targeting agent (TTA) technology. Lead product THIO targets cancers with hTERT expression.
Leadership and Structure
Vlad Vitoc is the Chairman, President and CEO. The company has a board of directors that oversees strategic decisions and management. The organizational structure is typical of a small biotech firm with departments focused on research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- THIO (Telomere-Targeting Agent): THIO is MAIA's lead drug candidate, currently in clinical trials for various cancers expressing hTERT. Specific market share data is not publicly available as it is still in clinical development. Competitors include companies developing similar targeted therapies, such as those focusing on telomerase inhibition or immunotherapy.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and heavily regulated. There is high demand for new cancer therapies, with ongoing research and development efforts focused on targeted therapies and immunotherapies.
Positioning
MAIA Biotechnology is a niche player focused on telomere targeting. Their competitive advantage lies in their specific technology and the potential to address unmet needs in cancers expressing hTERT.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. MAIA's TAM depends on the specific indications for which THIO is approved. If approved for multiple hTERT-expressing cancers, the TAM could be substantial. The company is positioned to address a segment of this larger market with its targeted approach.
Upturn SWOT Analysis
Strengths
- Proprietary telomere-targeting technology
- Experienced management team
- Potential to address unmet needs in specific cancer types
- Clinical-stage development
Weaknesses
- Reliance on a single lead product (THIO)
- Limited financial resources typical of small biotech companies
- Clinical trial risks and regulatory hurdles
- Unproven commercialization capabilities
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of THIO to other cancer indications
- Advancements in companion diagnostics to identify suitable patients
Threats
- Failure to demonstrate efficacy or safety in clinical trials
- Competition from other cancer therapies
- Regulatory delays or rejection
- Difficulty in securing funding
- Patent challenges
Competitors and Market Share
Key Competitors
- GERN
- CRIS
- IMMU
Competitive Landscape
MAIA is a small player competing against larger, more established pharmaceutical companies. Its success hinges on the uniqueness and efficacy of its telomere-targeting technology. Companies targetting similar types of oncology products are in a similar market.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's growth is tied to the progression of THIO through clinical trials. It has grown from preclinical stage to clinical stage, but has no products on the market.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates would be contingent on these milestones.
Recent Initiatives: Focus on advancing the clinical development of THIO, including initiating and completing clinical trials.
Summary
MAIA Biotechnology is a clinical-stage biopharmaceutical company with a focus on telomere-targeting cancer therapies. The company is in the risky clinical stage, therefore is not yet generating product revenue and carries high risk. Success depends heavily on the clinical trial outcomes of its lead drug candidate, THIO. Positive clinical results and strategic partnerships are crucial for the company's future growth.
Similar Companies
CRIS
Curis Inc
CRIS
Curis Inc
GERN
Geron Corporation
GERN
Geron Corporation
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news sources
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MAIA Biotechnology Inc.
Exchange NYSE MKT | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-07-28 | Co-Founder, President, CEO & Chairman of the Board of Directors Dr. Vlad Vitoc M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://maiabiotech.com |
Full time employees 13 | Website https://maiabiotech.com | ||
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.